TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The CDC’s updated 2026 antimicrobial-resistance report identifies 19 pathogens at threat levels ranging from concerning to urgent, plus six potential threats on a watch list. The agency estimates the pathogens collectively cause 9.7 million infections and 50,800 deaths annually in the United States; that total is not attributed to the four urgent drug-resistant pathogens alone.
The CDC’s updated 2026 antimicrobial-resistance report lists 19 pathogens as threats to public health and identifies six more as potential threats to monitor. The agency estimates that the pathogens together cause 9.7 million infections and 50,800 deaths annually in the United States; the figure covers the report’s listed pathogens collectively, not just the four drug-resistant organisms placed in its top “urgent” category.
The CDC ranks the 19 pathogens at levels from concerning and serious to urgent, reflecting the agency’s assessment of their public-health threat. The four drug-resistant organisms at the top tier are Candida auris (also called Candidozyma auris), carbapenem-resistant Acinetobacter, carbapenem-resistant Enterobacterales and drug-resistant Neisseria gonorrhoeae.
The report also changes the status of several organisms. Drug-resistant N. meningitidis is listed as a serious threat requiring prompt, sustained action. Drug-resistant dermatophytes, drug-resistant Haemophilus influenzae and nontuberculous mycobacteria were added to the watch list, which covers potential threats where disease burden is uncertain. Clostridioides difficile moved from urgent to serious; the report links the change in part to infection-prevention efforts and declining case numbers since 2011.
Some of the report’s U.S. figures are specific to 2023. The CDC estimates carbapenem-resistant Acinetobacter caused 9,497 hospitalizations and 817 deaths that year, while carbapenem-resistant Enterobacterales caused 14,878 hospitalizations and an estimated 1,252 deaths. Drug-resistant gonorrhea caused an estimated 787,000 infections. Those figures should not be confused with the report’s broader annual totals for all listed pathogens.
Risks for Patients and Care
Antimicrobial resistance can make infections harder to treat when medicines that once worked become less effective. The CDC’s findings matter beyond the direct disease burden: drug-resistant infections can complicate care for people who are already seriously ill, including patients receiving treatment in hospitals or long-term care facilities.
Wendy Armstrong, president of the Infectious Diseases Society of America, said in a statement that resistant infections can prolong hospital stays and raise health-care costs. She also warned that they can make it harder for clinicians to provide care such as chemotherapy, organ transplants and joint replacements safely. These are her comments on the broader clinical consequences, rather than a separate CDC estimate of those effects.
The individual pathogens pose different risks. C. auris can cause severe infections, particularly in people with serious underlying conditions, while carbapenem-resistant Acinetobacter is a concern in hospitals and nursing homes. Drug-resistant gonorrhea can limit treatment options for a common sexually transmitted infection. The report’s combined death estimate signals a substantial public-health burden, but does not mean every listed pathogen has the same level of risk or impact.
Products Worth Considering
Therabody JetBoots Prime Wireless Compression Boots (Short, Under 29-Inch Inseam)
Hyperice Normatec Elite Wireless Compression Boots
Hyperice Normatec 3 Full-Leg Compression Boots, Standard Size
As an affiliate, we earn on qualifying purchases.
How the CDC Reclassified Pathogens
The 2026 report updates the CDC’s assessment of pathogens with resistance to antimicrobial medicines. It groups organisms by threat level and maintains a separate watch list for emerging agents whose impact is not yet clear. The categories help distinguish established high-priority threats from organisms that warrant monitoring as evidence develops.
The report describes a sharp rise in reported U.S. C. auris cases: from 48 in 2016, when the infection was first reported in the country, to 4,523 in 2023. For gonorrhea, it says 55.4% of U.S. cases in 2023 were resistant to at least one of six antibiotics or had elevated minimum inhibitory concentrations. These measures are specific to their stated years and definitions; they are not direct comparisons of all resistant infections.
There have also been recent drug approvals relevant to gonorrhea. The source report says the FDA approved gepotidacin (Blujepa) and zoliflodacin (Nuzolvence) the previous year, describing them as the first new antibiotics for gonorrhea in decades. The updated CDC report does not, in the supplied material, quantify how those medicines have affected resistance or patient outcomes.
“These numbers are alarming by any measure, but they are particularly sobering when infectious diseases physicians connect real patients with these statistics in their everyday experience.”
— Wendy Armstrong, president of the Infectious Diseases Society of America
Limits of the Report’s Estimates
The headline total of 50,800 annual deaths is an agency estimate covering the pathogens named in the report. The supplied material does not break that combined figure down by each organism or provide the estimation methods, confidence ranges or a single year of measurement for the total. It should not be read as the annual death toll from the four urgent drug-resistant pathogens alone.
The CDC’s watch list also reflects uncertainty: the agency identifies potential threats, but their disease burden may not yet be established. The supplied report summary does not give detailed burden estimates for the newly added watch-list organisms or specify when their classifications might be revisited. It is also unclear from the available material how the new report’s overall estimates compare with earlier editions on a like-for-like basis.
Policy and Surveillance Ahead
The CDC’s report calls attention to monitoring and action against resistant infections, but the supplied material does not announce a specific new federal response or implementation timetable. Surveillance of the four urgent pathogens and the six watch-list organisms will be important for tracking whether their spread or public-health impact changes.
Armstrong urged Congress to pass the PASTEUR Act, which would create a federal program to support development of antimicrobial drugs for high-priority pathogens and infections. She said versions of the bill remained stalled in congressional committees. The next clear policy milestone would be congressional action; no timetable for a vote is provided in the source material.
Key Questions
What does the CDC estimate about these pathogens?
The CDC estimates that the pathogens covered by its 2026 report collectively cause 9.7 million infections and 50,800 deaths annually in the United States. The figures apply to the listed pathogens as a group, not only the four organisms classed as urgent.
Which organisms are on the urgent list?
The four drug-resistant urgent threats named in the report are Candida auris, carbapenem-resistant Acinetobacter, carbapenem-resistant Enterobacterales and drug-resistant Neisseria gonorrhoeae.
Why did C. difficile move to a lower category?
The report moved Clostridioides difficile from urgent to serious. The source summary says the change was driven in part by infection-prevention measures and declining case numbers since 2011.
What is the CDC watch list?
It is a list of potential threats for which the disease burden may be uncertain. The 2026 report adds drug-resistant dermatophytes, drug-resistant Haemophilus influenzae and nontuberculous mycobacteria, among six watch-list pathogens.
Does the report say the four urgent pathogens cause 50,800 deaths?
No. The 50,800 estimate covers the report’s listed pathogens collectively. The supplied report material does not assign that total to the four urgent drug-resistant organisms alone.
Source: medpagetoday.com
